Milazzotto F, Carelli M, Citone C, Di Marcotullio G, Giampaolo P, Malinconico U, Polizzi C, Tubaro M, Giovannini E, Boccardi L
Coronary Care Unit, Echocardiography Service, S. Camillo Hospital, Rome, Italy.
Semin Thromb Hemost. 1989 Oct;15(4):464-9. doi: 10.1055/s-2007-1002745.
The results of this preliminary clinical trial confirm the thrombolytic effect of defibrotide demonstrated in preclinical models; demonstrate the positive influence of the product on the natural history of early AMI; suggest that the optimal dosage range should include not less than 1.6 gm of defibrotide during the first hour of treatment; and justify further commitment in the study of defibrotide also beyond the scope of treating AMI.
